
Rui Zhou
Guangdong Pharmaceutical University
Cognitive reserve, plasma proteomics, and adverse kidney outcomes
Nephropathy, often known as renal disease or kidney damage, is the medical term for kidney disease. There are several forms of nephritis, an inflammatory kidney disease, depending on where the inflammation is present. Blood tests can be used to identify inflammation. Nephrosis is a kidney condition without inflammation. Nephrotic syndrome and nephritic syndrome are conditions that can result from nephrosis and nephritis, respectively. Kidney disease often results in a partial loss of renal function and can lead to kidney failure, which is the total loss of kidney function. The last stage of kidney disease, renal failure, can only be treated with dialysis or a kidney transplant. Chronic renal disease is characterised by persistent, structurally or functionally abnormal kidney conditions that last for longer than three years. Acute renal injury, as it is now known, is characterised by a precipitous decline in kidney function over a period of seven days. There are several therapeutic options due to the rising frequency of chronic renal disease. For information on the condition and operation of the kidneys, people can undergo blood or urine tests. Dialysis and kidney transplants are the two most common treatments for serious renal disease. Dialysis is a medical procedure that purges fluid and waste from a person's blood, acting as an artificial kidney. This is carried out via a device. Transplanting a healthy kidney from a donor into a person with kidney disease is known as a kidney transplant. The success of each of these options varies, and both have advantages and disadvantages.

Guangdong Pharmaceutical University
Cognitive reserve, plasma proteomics, and adverse kidney outcomes
Background: Cognitive Reserve (CR) may protect against age-related diseases, but its relationship with kidney outcomes and underlying proteomic mechanisms is unclear. We examined associations of CR…
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Oral and poster slots for original Kidney Diseases work, reviewed by the scientific committee.
Meet public health researchers, educators, and policy leaders from around the world across three days.
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Plenary lectures from leading voices shaping Kidney Diseases research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Kidney Diseases track is a dedicated stream within IPHC 2027 covering the latest research, innovation, and best practice in Kidney Diseases. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Public health researchers, practitioners, epidemiologists, educators, doctoral students, and policy leaders with an interest in Kidney Diseases are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IPHC 2027 is a hybrid conference — attend the Kidney Diseases track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.